Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.44 |
| ▸ | NAAA | Q02083 | 4/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.32 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008890 | 0.80 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL13698385 | 0.79 | GCKR (0.49) | HSD11B1NAAA | |
| SCHEMBL2011821 | 0.78 | L3MBTL1 (0.43) | HSD11B1 | |
| SCHEMBL2007974 | 0.77 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL4685105 | 0.77 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL2011871 | 0.76 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL2006217 | 0.75 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL2006369 | 0.74 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL3067566 | 0.73 | CNR1 (0.38) | HSD11B1 | |
| SCHEMBL2012050 | 0.73 | MITF (0.43) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSD11B1 136/4885NAAA 3714/4885PFKFB3 4275/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSD11B1 136/4885NAAA 3714/4885PFKFB3 4275/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSD11B1 136/4885NAAA 3714/4885PFKFB3 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.